iNeo-Vac-R01

Phase 1Biologic

SSir Run Run Shaw Hospital

iNeo-Vac-R01 is one of 10 biologic programs targeting Digestive System Neoplasm. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Digestive System NeoplasmActive, not recruiting

Digestive System NeoplasmPhase 1

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Digestive System Neoplasm

#DrugCompanyPhaseTrials

Inderal

WWyeth-Lederle Vaccines

Beyfortus

Herceptin

Pyrotinib

HHengrui Therapeutics, Inc.

Adrucil

1 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 7

LP002

TTaizhou HoudeAoke Biomedical Co., Ltd.

Phase 1

1 8

IM96 CAR-T Cells

BBeijing Immunochina Medical Science & Technology Co., Ltd.

Phase 1

1 9

iNeo-Vac-R01

SSir Run Run Shaw Hospital

Phase 1

3 10

Personalized MRNA Tumor Vaccine

SStemirna Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Recruiting

Biliary Malignant Tumors

NCT07368803

Q4 2027

Phase 1Recruiting

Digestive System Neoplasm

NCT06019702

Phase 1Recruiting

Digestive System Neoplasm

NCT06026800

Phase 1Recruiting

Digestive System Neoplasm

NCT06026774

Clinical

Trials by Indication[1]

Digestive System Neoplasm3 trials

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms

Recruiting·SSir Run Run Shaw Hospital·Phase 1·NCT06019702·20 enrolled

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms

Recruiting·SSir Run Run Shaw Hospital·Phase 1·NCT06026800·20 enrolled

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms

Recruiting·SSir Run Run Shaw Hospital·Phase 1·NCT06026774·20 enrolled

Biliary Malignant Tumors1 trial

Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection

Recruiting·YYifan Wang·Phase 1/2·NCT07368803·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for iNeo-Vac-R01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iNeo-Vac-R01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iNeo-Vac-R01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sir Run Run Shaw Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSir Run Run Shaw Hospital

iNeo-Vac-R01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Digestive System Neoplasm3 trials

Biliary Malignant Tumors1 trial

References

Drug Info

Quick Facts

Related News